For research use only. Not for therapeutic Use.
Dihydroergotamine(CAT: I026147) is a semi-synthetic ergot alkaloid that acts as a potent agonist at serotonin 5-HT1B and 5-HT1D receptors. It is primarily used in neurology research for its role in studying migraine pathophysiology and treatment. By constricting cranial blood vessels and inhibiting neurogenic inflammation, it helps elucidate mechanisms underlying migraine relief. Additionally, its interactions with dopaminergic and adrenergic receptors provide insights into broader neurological processes. Dihydroergotamine is a critical tool for advancing therapeutic research in migraine management and other neurological disorders.
| Catalog Number | I026147 |
| CAS Number | 511-12-6 |
| Synonyms | Dihydroergotamine; MAP0004; DHE; MAP 0004; MAP-0004; Levadex; |
| Molecular Formula | C33H37N5O5 |
| Purity | 98% |
| Solubility | Soluble in DMSO |
| Appearance | Solid powder |
| Storage | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
| IUPAC Name | (6aR,9R,10aR)-N-((2R,5S,10aS,10bS)-5-benzyl-10b-hydroxy-2-methyl-3,6-dioxooctahydro-8H-oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl)-7-methyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline-9-carboxamide |
| InChI | InChI=1S/C33H37N5O5/c1-32(35-29(39)21-15-23-22-10-6-11-24-28(22)20(17-34-24)16-25(23)36(2)18-21)31(41)38-26(14-19-8-4-3-5-9-19)30(40)37-13-7-12-27(37)33(38,42)43-32/h3-6,8-11,17,21,23,25-27,34,42H,7,12-16,18H2,1-2H3,(H,35,39)/t21-,23-,25-,26+,27+,32-,33+/m1/s1 |
| InChIKey | LUZRJRNZXALNLM-JGRZULCMSA-N |
| SMILES | [H][C@@]12CC3=CNC4=C3C([C@@]1([H])C[C@@H](C(N[C@@]5(C)C(N6[C@@H](CC7=CC=CC=C7)C(N8CCC[C@]8([C@]6(O)O5)[H])=O)=O)=O)CN2C)=CC=C4 |
